Darwin Global Management is an investment fund managing more than $366 billion ran by John Legge. There are currently 3 companies in Mr. Legge’s portfolio. The largest investments include Ambrx Biopharma and TG Therapeutics Inc, together worth $505 billion.
As of 7th August 2023, Darwin Global Management’s top holding is 16,688,636 shares of Ambrx Biopharma currently worth over $275 billion and making up 44.9% of the portfolio value.
Relative to the number of outstanding shares of Ambrx Biopharma, Darwin Global Management owns more than 0.4% of the company.
In addition, the fund holds 9,278,439 shares of TG Therapeutics Inc worth $230 billion, whose value fell 46.7% in the past six months.
The third-largest holding is Argenx Se worth $107 billion.
Currently, Darwin Global Management's portfolio is worth at least $366 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Darwin Global Management office and employees reside in St. Helier, Jersey. According to the last 13-F report filed with the SEC, John Legge serves as the Chief Financial Officer and Chief Compliance Officer at Darwin Global Management.
In the most recent 13F filing, Darwin Global Management revealed that it had increased its stake in
Ambrx Biopharma and bought 5,384,063 additional shares worth around $78 million.
This means they effectively own 0.4% of the company.
Ambrx Biopharma makes up
54.4%
of the fund's Health Care sector allocation and has decreased its share price by approximately 0.1% in the past year.
On the other hand, there are companies that Darwin Global Management is getting rid of from its portfolio.
Darwin Global Management closed its position in Keros Therapeutics on 14th August 2023.
It sold the previously owned 31,386 shares for $1.34 billion.
John Legge also disclosed a decreased stake in TG Therapeutics Inc by 0.1%.
This leaves the value of the investment at $230 billion and 9,278,439 shares.
The two most similar investment funds to Darwin Global Management are Stewart & Patten Co and Jgp Wealth Management. They manage $612 billion and $611 billion respectively.
Darwin Global Management’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 82.6% of
the total portfolio value.
The fund focuses on investments in the United States as
66.7% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
33% of the total holdings value.
On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $611 million.
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Ambrx Biopharma Inc. |
47.63%
16,688,636
|
$274,694,949,000 | 44.91% |
| TG Therapeutics Inc |
11.22%
9,278,439
|
$230,476,425,000 | 37.68% |
| Argenx Se |
4.16%
273,343
|
$106,529,967,000 | 17.42% |
| Keros Therapeutics, Inc. |
Closed
31,386
|
$1,340,182,000 | |
| No transactions found | |||
| Showing first 500 out of 4 holdings | |||